{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:21:56Z","timestamp":1767144116599,"version":"build-2238731810"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Severance Hospital Research fund for Clinical excellence","award":["C-2023-0011"],"award-info":[{"award-number":["C-2023-0011"]}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2024-0114"],"award-info":[{"award-number":["6-2024-0114"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment option for patients with relapsed or refractory lymphoid malignancies. However, the prognostic factors influencing survival outcomes in these patients remain poorly defined. This study aimed to evaluate the clinical variables associated with progression-free survival (PFS) and overall survival (OS) in patients undergoing allo-SCT for lymphoid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed 58 patients who underwent allo-SCT for lymphoid malignancies, including B-cell lymphoma (BCL,\n                      <jats:italic>n<\/jats:italic>\n                      = 20), Hodgkin lymphoma (\n                      <jats:italic>n<\/jats:italic>\n                      = 3), multiple myeloma (\n                      <jats:italic>n<\/jats:italic>\n                      = 9), natural killer\/T-cell lymphoma (NK\/TCL,\n                      <jats:italic>n<\/jats:italic>\n                      = 4), and T-cell lymphoma (TCL,\n                      <jats:italic>n<\/jats:italic>\n                      = 22). Clinical factors such as HLA matching and post-transplant response status were assessed for their association with survival outcomes using univariate and multivariate analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median PFS and OS were 27.4 months and 30.6 months, respectively. In univariate analysis, both HLA matching and complete remission (CR) status after transplantation were associated with superior PFS and OS. However, multivariate analysis identified only post-transplant CR as an independent predictor of improved survival. Subgroup analysis revealed that HLA matching was significantly associated with better PFS in patients with BCL and NK\/TCL, and with better OS only in BCL. Post-transplant CR was consistently associated with improved PFS and OS across BCL, NK\/TCL, and TCL subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Post-transplant response is a key prognostic factor influencing survival in allo-SCT for lymphoid malignancies. Achieving complete remission after transplantation may help guide post-SCT management and risk-adapted therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-025-00060-y","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:22:36Z","timestamp":1739172156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy"],"prefix":"10.1007","volume":"60","author":[{"given":"Hyungsoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haerim","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Won","family":"Kook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Ri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunsoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"60_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5045\/br.2023.2023177","volume":"58","author":"H Chung","year":"2023","unstructured":"Chung H, Cho H. Recent advances in cellular immunotherapy for lymphoid malignancies. Blood Res. 2023;58:166\u201372.","journal-title":"Blood Res"},{"key":"60_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jcyt.2024.05.002","volume":"26","author":"J Mariotti","year":"2024","unstructured":"Mariotti J, Zucchinetti C, Giordano L, et al. Allogeneic transplantation after immunotherapy for relapsed\/refractory non-Hodgkin lymphoma: a comparison with a historical cohort. Cytotherapy. 2024;26:1163\u20139.","journal-title":"Cytotherapy"},{"key":"60_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jcyt.2020.12.007","volume":"23","author":"J Tanaka","year":"2021","unstructured":"Tanaka J. Recent advances in cellular therapy for malignant lymphoma. Cytotherapy. 2021;23:662\u201371.","journal-title":"Cytotherapy"},{"key":"60_CR4","doi-asserted-by":"publisher","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","volume":"4","author":"J Du","year":"2021","unstructured":"Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e219807.","journal-title":"JAMA Netw Open"},{"key":"60_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.bbmt.2013.01.003","volume":"19","author":"HT Kim","year":"2013","unstructured":"Kim HT, Armand P. Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. Biol Blood Marrow Transplant. 2013;19:860\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"60_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/ejh.13226","volume":"102","author":"I Garcia-Cadenas","year":"2019","unstructured":"Garcia-Cadenas I, Yanez L, Jarque I, et al. Frequency, characteristics, and outcome of PTLD after allo-SCT: a multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019;102:465\u201371.","journal-title":"Eur J Haematol"},{"key":"60_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2013.09.012","volume":"42","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp Hematol. 2014;42:39\u201345.","journal-title":"Exp Hematol"},{"key":"60_CR8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3324\/haematol.2020.248187","volume":"106","author":"JP Cooper","year":"2021","unstructured":"Cooper JP, Storer BE, Granot N, et al. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica. 2021;106:1599\u2013607.","journal-title":"Haematologica"},{"key":"60_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12288-014-0497-7","volume":"31","author":"JS Wang","year":"2015","unstructured":"Wang JS, Wang Z, Wang YN, Wu L, Fu L, Wei N. Allogeneic hematopoietic stem cell transplantation: a salvage treatment for relapsed or refractory lymphoma. Indian J Hematol Blood Transfus. 2015;31:426\u201333.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"60_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6:920\u201330.","journal-title":"Blood Adv"},{"key":"60_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41375-022-01782-z","volume":"37","author":"PM Bruch","year":"2023","unstructured":"Bruch PM, Dietrich S, Finel H, et al. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia. 2023;37:465\u201372.","journal-title":"Leukemia"},{"key":"60_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4143\/crt.2024.074","volume":"56","author":"HJ Shin","year":"2024","unstructured":"Shin HJ, Kim DY, Kim K, et al. Nation-wide retrospective analysis of allogeneic stem cell transplantation in patients with multiple myeloma: a study from Korean Multiple Myeloma Working Party (KMM1913). Cancer Res Treat. 2024;56:956\u201366.","journal-title":"Cancer Res Treat"},{"key":"60_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","volume":"101","author":"HT Kim","year":"2016","unstructured":"Kim HT, Zhang MJ, Woolfrey AE, et al. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica. 2016;101:1260\u20136.","journal-title":"Haematologica"},{"issue":"96","key":"60_CR14","first-page":"e1","volume":"28","author":"M Malagola","year":"2022","unstructured":"Malagola M, Polverelli N, Rubini V, et al. GITMO registry study on allogeneic transplantation in patients aged >\/=60 years from 2000 to 2017: improvements and criticisms. Transplant Cell Ther. 2022;28(96):e1\u201311.","journal-title":"Transplant Cell Ther"},{"key":"60_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41409-023-01931-7","volume":"58","author":"C Michel","year":"2023","unstructured":"Michel C, Robin M, Morisset S, et al. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplant. 2023;58:534\u201343.","journal-title":"Bone Marrow Transplant"},{"key":"60_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3904\/kjim.2012.27.1.72","volume":"27","author":"HC Shin","year":"2012","unstructured":"Shin HC, Lee YJ, Moon JH, et al. Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. Korean J Intern Med. 2012;27:72\u201383.","journal-title":"Korean J Intern Med"},{"key":"60_CR17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","volume":"27","author":"S Genadieva-Stavrik","year":"2016","unstructured":"Genadieva-Stavrik S, Boumendil A, Dreger P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27:2251\u20137.","journal-title":"Ann Oncol"},{"key":"60_CR18","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.21873\/invivo.12515","volume":"35","author":"EH Jung","year":"2021","unstructured":"Jung EH, Shin DY, Hong J, et al. Identification of an optimal population for allogeneic hematopoietic stem cell transplantation in patients with mature T and NK cell neoplasms. In Vivo. 2021;35:2379\u201390.","journal-title":"In Vivo"},{"key":"60_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-023-00868-w","volume":"13","author":"DW Baek","year":"2023","unstructured":"Baek DW, Moon JH, Lee JH, et al. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation. Blood Cancer J. 2023;13:95.","journal-title":"Blood Cancer J"},{"key":"60_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1200\/JCO.1992.10.2.237","volume":"10","author":"EA Copelan","year":"1992","unstructured":"Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol. 1992;10:237\u201342.","journal-title":"J Clin Oncol"},{"key":"60_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41408-023-00900-z","volume":"13","author":"WM Schmidt","year":"2023","unstructured":"Schmidt WM, Perera ND, Buadi FK, et al. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. Blood Cancer J. 2023;13:126.","journal-title":"Blood Cancer J"},{"issue":"903","key":"60_CR22","first-page":"e1","volume":"30","author":"SR Solomon","year":"2024","unstructured":"Solomon SR, Bachier-Rodriguez L, Bashey A, et al. Impact of graft-versus-host disease on relapse and nonrelapse mortality following posttransplant cyclophosphamide-based transplantation. Transplant Cell Ther. 2024;30(903):e1\u20139.","journal-title":"Transplant Cell Ther"},{"key":"60_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/bmt.2014.310","volume":"50","author":"S Iacobelli","year":"2015","unstructured":"Iacobelli S, de Wreede LC, Schonland S, et al. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015;50:505\u201310.","journal-title":"Bone Marrow Transplant"},{"key":"60_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12:217\u201326.","journal-title":"Curr Hematol Malig Rep"},{"key":"60_CR25","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","volume":"100","author":"R Wullenkord","year":"2021","unstructured":"Wullenkord R, Berning P, Niemann AL, et al. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol. 2021;100:2733\u201344.","journal-title":"Ann Hematol"}],"updated-by":[{"DOI":"10.1007\/s44313-025-00083-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000}}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00060-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:36:06Z","timestamp":1748255766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00060-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00060-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s44313-025-00083-5","URL":"https:\/\/doi.org\/10.1007\/s44313-025-00083-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Severance Hospital, Seoul, Republic of Korea (IRB No. 4\u20132021-1597), and adhered to the ethical guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}